Preview Mode Links will not work in preview mode

This Week in Cardiology

Jul 14, 2023

Carotid stents, the paclitaxel story now closed, inclisiran, DOAC failures, and primary vs secondary prevention are the topics John Mandrola, MD, covers in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

I. Carotid Stenting CMS Proposal

Expanded Coverage of Carotid Stenting in CMS Draft Proposal

No Added Benefit From Revascularization in Low-Risk CAS

- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with Stenting

- Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy


- Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial 10.1161/STROKEAHA.120.030730

II. Paclitaxel

FDA: No Excess Mortality Risk From Paclitaxel Stents, Balloons for Peripheral Intervention

- FDA Statement

III. Inclisiran

FDA Expands Inclisiran Statin-Adjunct Indication to Include Primary Prevention

- ORION 10-11 Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

- Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

- Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

IV. DOAC Failure

Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant

V. Primary or Secondary Prevention

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact